U.S. Commercial Services Stock News

Kailera Therapeutics, NasdaqGS:KLRA, completed its initial public offering and began trading as a public company. The company implemented a restated certificate of incorporation and amended bylaws that adjust board structure, shareholder rights, and forum selection. Kailera Therapeutics was added to the NASDAQ Composite Index, increasing its visibility among index-tracking investors. With NasdaqGS:KLRA now trading at $25.15, Kailera Therapeutics has moved into the public markets with fresh...

Monte Rosa Therapeutics recently presented preclinical data at the AACR 2026 meeting in San Diego showing its first-in-class cyclin E1-directed molecular glue degrader, MRT-55811, produced selective cyclin E1 degradation, downstream pathway suppression, and tumor regression in CCNE1-amplified models. The work suggests a potential way to directly target a historically “undruggable” oncogene across multiple CCNE1-amplified solid tumors while sparing non-amplified cells. We’ll now look at how...

In April 2026, Remitly Global, Inc. expanded its WhatsApp Send service to more countries and introduced a new “Request Money” feature that lets Elektra bank customers in Mexico initiate transfers directly within WhatsApp, without requiring an app download. This enhancement deepens Remitly’s integration into everyday messaging habits while early data shows strong growth in WhatsApp-driven sessions, suggesting rising customer reliance on chat-based remittances for rate checks, transactions,...

FedEx stock snapshot and recent performance FedEx (FDX) has drawn investor attention after recent trading, with the share price closing at $393.67 and short term movements including a 2.4% decline over the past day and a 1.5% gain over the past week. See our latest analysis for FedEx. Recent moves sit within a stronger trend, with a 34.3% year to date share price return and an 83.15% 1 year total shareholder return suggesting momentum has been building and risk perceptions shifting. If...

American Financial Group (AFG) opened 2026 earnings season with Q1 results that follow a solid 2025 finish, where Q4 revenue was US$2.0b, basic EPS came in at US$3.58, and net income excluding extra items was US$299m. Over recent quarters the company has seen revenue range from US$1.8b to US$2.3b, while quarterly basic EPS moved from US$1.84 in Q1 2025 to US$3.58 in Q4 2025. This gives a clear view of how profits have tracked alongside a trailing 12 month net margin of 10.6% compared with...

Cellebrite recently appointed Shiven Ramji, formerly of Okta/Auth0, as President of Products and Technology, succeeding Ronnen Armon following a transition period, and it is preparing to report its March 2026-quarter results on 14 May with consensus expectations for higher earnings and revenue than the prior year. Ramji’s track record leading a very large annual recurring revenue business and focus on AI adoption across Cellebrite’s platform may influence how investors assess the company’s...

If you are wondering whether Northwest Natural Holding is fairly priced, expensive, or a potential value idea right now, this article walks through what the current numbers indicate. The stock last closed at US$52.86, with returns of 13.1% year to date and 27.7% over the past year, so recent performance may be prompting fresh questions about risk and reward. Recent news coverage has largely focused on how regulated utilities like Northwest Natural Holding fit into portfolios that may be...

Ermenegildo Zegna (ZGN) shares reacted after the group reported Q1 2026 revenue growth of 2.5% year on year, with 7.4% organic growth supported by Direct to Consumer sales and stronger results in the Americas. See our latest analysis for Ermenegildo Zegna. The Q1 2026 update comes on the back of strong recent momentum, with a 30 day share price return of 14.55% and a 90 day share price return of 43.15%. The 1 year total shareholder return of 59.13% points to gains that go beyond short term...

If you are wondering whether On Holding's current share price reflects its true value, this breakdown will help you line up the story the numbers are telling. The stock recently closed at US$34.54, with returns of 4.7% decline over the past week, 0.7% decline over the past month, and 26.4% decline year to date, while the 1-year return sits at 29.4% decline and the 3-year return at 1.9%. Recent coverage has focused on how the stock's pullback contrasts with its longer term performance,...

CF Industries Holdings, Inc. recently declared a US$0.50 per-share quarterly dividend on its common stock, payable on May 29, 2026, to shareholders of record as of May 15, 2026, alongside shareholder approval of all director nominees, say-on-pay, and auditor ratification. Management highlighted strong 2025 operating achievements, including 10.10 million tons of ammonia production, record low safety incidents, US$1.70 billion returned to shareholders, and progress on low-carbon ammonia and...

Wondering whether MercadoLibre at around US$1,850 per share still offers value, or if the best days of the stock are behind it? This article walks through the numbers so you can judge for yourself. The share price has moved by 0.8% over the last 7 days and 7.6% over the last 30 days, while the year to date return is a 6.3% decline and the 1 year return is an 18.9% decline, set against a 3 year return of 48.8% and a 5 year return of 24.9%. Recent headlines around MercadoLibre have focused on...

Melco Resorts & Entertainment (NasdaqGS:MLCO) heads into its Q1 2026 update with recent quarterly numbers that put revenue at about US$1.3b in Q4 2025 and basic EPS at US$0.16. This caps off a year where trailing twelve month EPS reached US$0.46 on revenue of roughly US$5.2b. Over the past few quarters, the company has seen revenue range between US$1.2b and US$1.3b per quarter, while basic EPS moved from US$0.08 in Q1 2025 to US$0.19 in Q3 before landing at US$0.16 in Q4. This result comes...

Ares Management (NYSE:ARES) has appointed Peter Ogilvie as Chief Operating Officer and Head of Strategy. Ogilvie is tasked with driving global growth initiatives across the firm’s platform. The move reflects a leadership shift that could influence how Ares pursues expansion and integration of future acquisitions. Ares Management, trading at $119.0, has mixed recent performance, with a 3.3% return over the past week and 12.5% over the past month, set against a 28.5% decline year to date and...

Q2 Holdings (NYSE:QTWO) has introduced new AI driven fraud prevention tools focused on continuous account takeover protection. The company has also rolled out Q2 Treasury Fulfillment, a solution aimed at streamlining and automating treasury onboarding for commercial clients. Both features expand Q2's digital banking platform beyond its recent earnings updates, targeting fraud risk and onboarding friction for financial institutions. Q2 Holdings enters this product update cycle with its...

Halozyme Therapeutics (NasdaqGS:HALO) has appointed Darren Snellgrove as Chief Financial Officer. Snellgrove is described as a seasoned financial executive with extensive biopharmaceutical experience. The CFO appointment represents a key leadership change that may influence future capital allocation and corporate priorities. For investors following biopharma platforms, Halozyme Therapeutics focuses on drug delivery technologies and partnerships with larger pharmaceutical companies. A CFO...

Caterpillar has caught the eye of many investors lately, and if you are wondering whether the current share price offers good value, the numbers provide a useful starting point. At a last close of US$889.67, the stock has delivered returns of 7.1% over 7 days, 21.8% over 30 days, 48.7% year to date, 177.8% over 1 year, 332.8% over 3 years and 303.7% over 5 years. That naturally raises questions about how much of the story is already reflected in the price. Recent headlines around Caterpillar...

In late April 2026, Merck reported stronger-than-expected first-quarter results, raised its full-year revenue and earnings guidance, and secured FDA approval for IDVYNSO, a complete two-drug HIV-1 regimen for virologically suppressed adults. Together with advancing oncology programs such as KEYTRUDA-based regimens and WELIREG in renal cell carcinoma, these developments reinforce Merck’s efforts to broaden growth drivers ahead of expected pressure on legacy products. We’ll now examine how...

Xenon Pharmaceuticals (XENE) is back in focus after presenting Phase 3 X-TOLE2 data for azetukalner in adults with focal onset seizures, supported by long term X-TOLE extension and real world no titration feedback. See our latest analysis for Xenon Pharmaceuticals. The latest clinical update has arrived after a strong few quarters for the stock, with a 36.87% 90 day share price return and a 46.63% 1 year total shareholder return that suggest momentum has been building around Xenon’s lead...

Tempus AI (TEM) is back in focus after TIME named it one of the 10 Most Influential Health and Life Science Companies of 2026, alongside fresh oncology partnerships and upcoming earnings and Investor Day milestones. See our latest analysis for Tempus AI. Tempus AI’s recent recognition and oncology tie ups come as the share price trades at US$55.0, with a 16.06% 30 day share price return but an 11.80% year to date share price decline and a 3.61% 1 year total shareholder return decline. This...

Arteris (AIP) shares were in focus after the company announced a new collaboration with MIPS, a GlobalFoundries company, to support physical AI computing platforms across automotive, robotics, and embedded computing markets. See our latest analysis for Arteris. The collaboration news arrives after a strong run in Arteris shares, with a 30 day share price return of 64.96% and a year to date share price return of 85.82%. The 1 year total shareholder return is 330.80% and the 3 year total...

Rocket Companies, which owns Redfin, is heading into its 7 May 2026 earnings release with analysts expecting higher quarterly revenue and a year-over-year earnings increase, as recent estimate revisions have turned more positive. Fresh housing data from Redfin showing rising pending home sales, stronger mortgage-application activity and slightly improved affordability highlights how macro housing trends are feeding directly into Rocket’s operating backdrop. Next, we’ll examine how improving...

GoDaddy (GDDY) opened 2026 with Q1 revenue of US$1.27 billion and basic EPS of US$1.61, setting the tone for how its hosting and domains business is translating scale into earnings. The company reported quarterly revenue of US$1.19 billion in Q1 2025 and US$1.27 billion in Q1 2026, with basic EPS moving from US$1.55 to US$1.61 over the same period, while trailing twelve month EPS reached US$6.39 on US$5.02 billion of revenue. With net profit margin at 17.3% over the last year, these results...

Shopify (SHOP) is back in focus after recent 2025 results framed it as a profitable compounder, with management outlining broad based growth, AI powered commerce initiatives, and a confident revenue outlook. See our latest analysis for Shopify. The stock has been volatile around recent AI commerce updates and investor commentary, with a 5.4% 1 day share price return and a year to date share price decline of 18.8%, set against a 1 year total shareholder return of 28.6% and a 3 year total...

Pioneer Bancorp (PBFS) opened Q1 2026 with total revenue of US$23.8 million and basic EPS of US$0.22, setting the tone for how its earnings story is evolving after a year in which trailing 12 month net income reached US$19.8 million. Over recent quarters, the bank has reported total revenue ranging from US$21.2 million in Q4 2024 to US$24.5 million in Q4 2025. Over the same span, quarterly basic EPS moved between US$0.13 and US$0.26, giving investors a clearer view of how profits have tracked...